Xenetic BiosciencesXBIO
13F holders, Q2 2024 (June 30)5holders −2
1new positions
3sold out
$4.17avg. 13F price*
At the end of Q2 2024, 5 institutions reported holding Xenetic Biosciences Inc. (XBIO) in their 13F filings, down 2 from Q1 2024. 1 opened new positions and 3 sold out. The largest holders were Geode Capital Management, LLC ($50K), JTC Employer Solutions Trustee Ltd ($11K) and UBS Group AG ($741).
- Company
- Xenetic Biosciences Inc.
- CUSIP
- 984015602
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $45 |
| Exits | 3 | $11K |
All 13F filers, Q1 2024 → Q2 2024: 1,001 shares bought and 5,729 shares sold, net −4,728 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Geode Capital Management, LLC | 0.00% | Add +9.0% | 11,988 | $50K |
| JTC Employer Solutions Trustee Ltd | 0.00% | No change | 2,700 | $11K |
| UBS Group AG | 0.00% | Reduce -94.1% | 182 | $741 |
| Bank of America Corp. | 0.00% | New | 11 | $45 |
| Morgan Stanley | 0.00% | No change | 1 | $4 |
"% of holder's portfolio" is XBIO's weight in each manager's 13F, not the share of Xenetic Biosciences Inc. the manager owns.